Daye Tampon Trial for Ovarian Cancer
Analysis based on 11 articles · First reported Feb 20, 2026 · Last updated Feb 21, 2026
This medical breakthrough could significantly impact the biotechnology and healthcare sectors by introducing a novel, non-invasive ovarian cancer screening method. Daye, as the developer of the diagnostic tampon, stands to gain substantial market share if the trial proves successful, potentially leading to increased investment and competition in early cancer detection technologies.
A groundbreaking clinical trial, named Violet, is underway in Southampton to investigate whether a specialist medical tampon developed by Daye can detect early indicators of ovarian cancer. The trial, led by Dr. Jemma Longley of University Hospital Southampton and co-investigated by David Constable-Phelps, aims to identify minuscule biological markers (microRNAs) in vaginal fluid. Approximately 250 women, including those with ovarian cancer and those with the BRCA gene mutation, are participating. The Eve Appeal has provided funding for the research. If successful, this non-invasive test could revolutionize ovarian cancer diagnosis, which is currently often detected at advanced stages, and pave the way for a larger trial.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard